Pharmaceutical composition for treating acute myelogenous leukemia

A composition and leukemia technology, which is applied in the field of pharmaceutical compositions for the treatment of leukemia, can solve problems such as no reports of combination therapy for leukemia, and achieve excellent results

Active Publication Date: 2019-08-20
宁波市鄞州人民医院
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] At present, there is no report on the combination of hom...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating acute myelogenous leukemia
  • Pharmaceutical composition for treating acute myelogenous leukemia
  • Pharmaceutical composition for treating acute myelogenous leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Weigh homoharringtonine 1.6g, 2-methyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazine- 1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one 0.4g, tartaric acid 1g were dissolved in an appropriate amount of hot water for injection, and then tartaric acid solution was slowly added Homoharringtonine and 2-methyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl) In the mixed solution of phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one, stir constantly to dissolve all the active ingredients, then add 10g of lactose and 15g of mannitol, and stir to dissolve , adjust the pH to 4 with 4% NaOH, add water for injection to 1000ml, filter aseptically, pack the filtrate into sterilized control vials according to 1ml / branch, freeze-dry in a freeze dryer for 24h, and press the cap. Sterilized butyl rubber stoppers, rolled aluminum caps, inspected and packaged.

Embodiment 2

[0046] Weigh homoharringtonine 1g, 2-methyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazine-1 -yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one 1g and tartaric acid 1g were respectively dissolved in an appropriate amount of hot water for injection, and then the tartaric acid solution was slowly added to Gao Sanjian phenetine and 2-methyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenyl In the mixed solution of amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one, stir continuously to dissolve all the active ingredients, then add 10g of lactose and 15g of mannitol, stir to dissolve, and use Adjust the pH to 4 with 4% NaOH, add water for injection to 1000ml, filter aseptically, pack the filtrate into sterilized controlled vials according to 1ml / vial, freeze-dry in a freeze dryer for 24 hours, and the gland has been sterilized Butyl rubber stoppers, rolled aluminum caps, inspection, and packaging.

Embodiment 3

[0048] Weigh homoharringtonine 1.8g, 2-methyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazine- 1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one 0.2g, tartaric acid 1g were dissolved in appropriate amount of hot water for injection, and then tartaric acid solution was slowly added Homoharringtonine and 2-methyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl) In the mixed solution of phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one, stir constantly to dissolve all the active ingredients, then add 10g of lactose and 15g of mannitol, and stir to dissolve , adjust the pH to 4 with 4% NaOH, add water for injection to 1000ml, filter aseptically, pack the filtrate into sterilized control vials according to 1ml / branch, freeze-dry in a freeze dryer for 24h, and press the cap. Sterilized butyl rubber stoppers, rolled aluminum caps, inspected and packaged.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition for treating acute myelogenous leukemia. The pharmaceutical composition comprises active ingredients of homoharringtonine and a Wee1 kinase inhibitor, wherein a weight ratio of the homoharringtonine to the Wee1 kinase inhibitor is 1:10 to 10:1. The pharmaceutical composition is significantly effective for treating leukemia, particularlyfor chronic myelogenous leukemia or acute myelogenous leukemia, and provides a whole novel approach to a co-administration regimen for development and treatment of the leukemia.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a medicine composition for treating leukemia. Background technique [0002] Leukemia is a cancer originating in the bone marrow, which refers to the uncontrolled and infinite proliferation of a large number of immature blood cell precursor cells that accumulate and infiltrate other tissues and organs, while inhibiting the production of normal blood cells. The initial symptoms of leukemia patients are often overlooked because they are not obvious. Common symptoms include fatigue, anemia, heart palpitations, shortness of breath, enlargement of liver, spleen, lymph nodes, and bone pain. At the same time, leukemia patients usually have complications caused by hematopoietic dysfunction, including: bleeding, fever, refractory infection, extremely high white blood cell count, dyspnea, confusion or organ failure and other symptoms. The exact etiology of leukemia is not very clear at present, po...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/55A61K31/522A61P35/02
CPCA61K31/522A61K31/55A61K45/06A61P35/02A61K2300/00
Inventor 陆滢叶佩佩
Owner 宁波市鄞州人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap